Cristina Bugés has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Laura Layos

    Department of Medical Oncology, Institut Català d’Oncologia (ICO) Badalona, 08916 Badalona, Spain

    2 shared publications
  • Andrés Felipe Cardona

    Clinical and Translational Oncology Group, Instituto de Oncología, Fundación Santa Fe de Bogotá, Colombia

    1 shared publication
  • Anna Pous

    Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08916 Badalona, Spain

    1 shared publication
  • Cinta Hierro

    Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, 08035 Barcelona, Spain

    1 shared publication
  • Cristina Queralt

    Program of predictive and personalized cancer medicine (PMPPC) Germans Trias i Pujol Research Institute (IGTP), Ctra. Can Ruti—Camí de les escoles s/n, 08916 Badalona, Spain

    1 shared publication
  • Diego Arango

    Group of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain

    1 shared publication

Latest Publications

  • Open Access

    HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

    by Anna Pous, Lucía Notario, Cinta Hierro, Laura Layos, Cristina Bugés

    Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients. However, gastric cancer still has high mortality rates and urgently requires new treatment strategies. The combination of immunotherapy with HER2-targeted therapies has shown synergistic effects in preclinical models, this being the rationale behind exploring this combination in clinical trials in locally advanced and metastatic settings. Additionally, the irruption of antibody–drug conjugates and other novel HER2-targeted agents has led to the development of numerous clinical trials showing promising results. This review presents the molecular mechanisms supporting the use of HER2-targeted drugs in combination with immunotherapy and provides an overview of the therapeutic scenario of HER2-positive disease. We focus on the role of immunotherapy but also summarize emerging therapies and combinations under clinical research that may change the standard treatment in HER-2 positive disease in the future.


  • Open Access

    Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

    by Vicenç Ruiz de Porras, Sara Bystrup, Sara Cabrero-De Las Heras, Eva Musulén, Luis Palomero, Maria Henar Alonso, Rocio Nieto, Diego Arango, Víctor Moreno, Cristina Queralt, et al.

    In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.


  • Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient

    by Cristina Bugés, Enric Carcereny, Teresa Moran, Andrés Felipe Cardona, Noemi Reguart, Laia Capdevila, Sara Cros, Rafael Rosell